A case report describes pathology-confirmed late radiation necrosis after stereotactic radiosurgery, with radiographic progression temporally associated with repeated COVID-19 vaccination.
A translational review proposes shared reporting and quality-assurance principles for model-dependent biological dose in proton, carbon-ion and boron neutron capture therapy.
A 4.5 mm isotropic margin covered most observed small-bowel occupancy despite craniocaudal displacements exceeding 20 mm in some patients.
Planning CT features added prognostic information for local and distant control but did not significantly improve overall or progression-free survival prediction.
Upright carbon ion treatment plans achieved target coverage, organ sparing and simulated robustness comparable with conventional supine plans.
A mean lung dose threshold of 12.70 grays strongly separated patients who developed radiation pneumonitis after adjuvant breast radiotherapy.
Iodine-125 doses of 140–160 grays were associated with longer median survival than 120–140 grays in recurrent glioblastoma.
Smaller base-of-tongue volume was associated with prolonged feeding-tube dependence after radiotherapy for oral cavity squamous cell carcinoma.
The framework linked complete planning and delivery data for 13,871 plans with 99.76% success across two clinics.
Escalating metabolically active disease to 73.5 Gy did not improve locoregional control, disease-free survival, or overall survival versus 66 Gy.
Spine proton ablative radiotherapy achieved 74% local control at one and two years, with no radiation myelopathy in a reirradiation-enriched cohort.
Medial retropharyngeal nodes were involved in 2.95% of German cases, but no recurrence occurred among patients whose elective volume omitted the region.
Only 12 eligible studies were found, with inconsistent methods and assumptions that limited meaningful comparison of particle therapy costs.
A single offline replan at fraction 15 captured most achievable dosimetric benefit in simulated head and neck proton therapy.
MRI-guided SBRT with 2-mm margins reduced low- and intermediate-dose exposure of neurovascular bundles and pudendal arteries versus CT-guided treatment.